| Name | Title | Contact Details |
|---|
ITM Isotopen Technologien München AG and its subsidiaries develop, produce and supply innovative diagnostic and therapeutic radionuclides and radiopharmaceuticals.
Intra-Cellular Therapies is a biopharmaceutical company developing novel drugs, leveraging technology from the lab of Nobel laureate Dr. Paul Greengard, for the treatment of neuropsychiatric and neurodegenerative diseases. The Company is developing its lead drug candidate, lumateperone, a first-in-class molecule, which is in Phase 3 clinical development for the treatment of schizophrenia, bipolar depression, and agitation associated with dementia, including Alzheimer`s disease. The Company is also utilizing its phosphodiesterase (PDE) platform and other proprietary chemistry platforms to develop drugs for the treatment of CNS and other disorders. The lead compound in the PDE platform, ITI-214, a PDE1 inhibitor is being developed for the treatment of CNS and non-CNS indications.
Oncology Therapeutics Network is a South San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Tavotek is a biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need.
SemBioSys Genetics is a Calgary, AB-based company in the Healthcare, Pharmaceuticals, and Biotech sector.